NCT01884623View on ClinicalTrials.gov

Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 6, 2013

Primary Completion Date

October 12, 2021

Study Completion Date

October 12, 2021

Conditions

Head Neck Cancer Squamous Cell Recurrent

Interventions

DRUG

Cetuximab

DRUG

Methotrexate

Trial Locations (1)

94805

Institut Gustave Roussy, Villejuif

All Listed Sponsors

collaborator

National Cancer Institute, France

OTHER_GOV

collaborator

Ligue contre le cancer, France

OTHER

collaborator

Merck Serono International SA

INDUSTRY

lead

Gustave Roussy, Cancer Campus, Grand Paris

OTHER

NCT01884623 - Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer | Biotech Hunter | Biotech Hunter